Anti-CTLA-4 immunotherapy does not deplete FOXP3 regulatory T cells (Tregs) in human cancers (Q56890805)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30054281 AND SRC:MED&resulttype=core&format=json

14 April 2020

title

Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3 Regulatory T Cells (Tregs) in Human Cancers (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30054281 AND SRC:MED&resulttype=core&format=json

14 April 2020

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30054281 AND SRC:MED&resulttype=core&format=json

14 April 2020

8

Antoni Ribas

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30054281 AND SRC:MED&resulttype=core&format=json

14 April 2020

6

Jennifer Wargo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30054281 AND SRC:MED&resulttype=core&format=json

14 April 2020

author name string

Anu Sharma

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30054281 AND SRC:MED&resulttype=core&format=json

14 April 2020

Sumit K Subudhi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30054281 AND SRC:MED&resulttype=core&format=json

14 April 2020

Jorge Blando

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30054281 AND SRC:MED&resulttype=core&format=json

14 April 2020

Jorge Scutti

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30054281 AND SRC:MED&resulttype=core&format=json

14 April 2020

Luis Vence

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30054281 AND SRC:MED&resulttype=core&format=json

14 April 2020

Padmanee Sharma

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30054281 AND SRC:MED&resulttype=core&format=json

14 April 2020

language of work or name

English

0 references

publication date

27 July 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30054281 AND SRC:MED&resulttype=core&format=json

14 April 2020

published in

Clinical Cancer Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30054281 AND SRC:MED&resulttype=core&format=json

14 April 2020

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30054281 AND SRC:MED&resulttype=core&format=json

14 April 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30054281 AND SRC:MED&resulttype=core&format=json

14 April 2020

page(s)

1233-1238

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30054281 AND SRC:MED&resulttype=core&format=json

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

14 April 2020

cites work

1 reference

12 December 2020

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

1 reference

12 December 2020

CTLA-4 can function as a negative regulator of T cell activation

1 reference

12 December 2020

Enhancement of antitumor immunity by CTLA-4 blockade

1 reference

12 December 2020

Immunologic self-tolerance maintained by CD25( )CD4( ) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4.

1 reference

12 December 2020

CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells

1 reference

12 December 2020

FOXP3 controls regulatory T cell function through cooperation with NFAT

1 reference

12 December 2020

Blockade of CTLA-4 on CD4 CD25 regulatory T cells abrogates their function in vivo

1 reference

12 December 2020

Foxp3 in control of the regulatory T cell lineage

1 reference

12 December 2020

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

1 reference

12 December 2020

CTLA4 blockade expands FoxP3 regulatory and activated effector CD4 T cells in a dose-dependent fashion

1 reference

12 December 2020

CTLA-4 blockade increases IFNgamma-producing CD4 ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

1 reference

12 December 2020

CTLA-4 control over Foxp3 regulatory T cell function

1 reference

12 December 2020

Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade

1 reference

12 December 2020

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

1 reference

12 December 2020

Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity.

1 reference

12 December 2020

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial

1 reference

12 December 2020

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

12 December 2020

Clinical Development of the Anti–CTLA-4 Antibody Tremelimumab

1 reference

12 December 2020

CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans

1 reference

12 December 2020

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

12 December 2020

Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer

1 reference

12 December 2020

viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia

1 reference

12 December 2020

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

1 reference

12 December 2020

Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells

1 reference

12 December 2020

The future of immune checkpoint therapy

1 reference

12 December 2020

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients

1 reference

12 December 2020

Combination cancer immunotherapies tailored to the tumour microenvironment

1 reference

12 December 2020

Influence of immunoglobulin isotype on therapeutic antibody function

1 reference

12 December 2020

Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab.

1 reference

12 December 2020

CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes

1 reference

12 December 2020

A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.

1 reference

12 December 2020

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.

1 reference

12 December 2020

10.1158/1078-0432.CCR-18-0762

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30054281 AND SRC:MED&resulttype=core&format=json

14 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30054281 AND SRC:MED&resulttype=core&format=json

14 April 2020

PubMed publication ID

30054281

1 reference